187 related articles for article (PubMed ID: 38243308)
1. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.
Rospo G; Chilà R; Matafora V; Basso V; Lamba S; Bartolini A; Bachi A; Di Nicolantonio F; Mondino A; Germano G; Bardelli A
Genome Med; 2024 Jan; 16(1):15. PubMed ID: 38243308
[TBL] [Abstract][Full Text] [Related]
2. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
[TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
[TBL] [Abstract][Full Text] [Related]
4. On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
Solomon A; Alteber Z; Bassan D; Sharbi-Yunger A; Esbit S; Tzehoval E; Eisenbach L
Int J Cancer; 2022 Jul; 151(1):107-119. PubMed ID: 35179790
[TBL] [Abstract][Full Text] [Related]
5. Constitutional MLH1 Methylation Is a Major Contributor to Mismatch Repair-Deficient, MLH1-Methylated Colorectal Cancer in Patients Aged 55 Years and Younger.
Hitchins MP; Dámaso E; Alvarez R; Zhou L; Hu Y; Diniz MA; Pineda M; Capella G; Pearlman R; Hampel H
J Natl Compr Canc Netw; 2023 Jul; 21(7):743-752.e11. PubMed ID: 37433431
[TBL] [Abstract][Full Text] [Related]
6. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.
Guo J; Tang B; Fu J; Zhu X; Xie W; Wang N; Ding Z; Song Z; Yang Y; Xu G; Xiao X
Cell Oncol (Dordr); 2024 Apr; 47(2):573-585. PubMed ID: 37847338
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.
Post CCB; Stelloo E; Smit VTHBM; Ruano D; Tops CM; Vermij L; Rutten TA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Nout RA; Crosbie EJ; Powell ME; Mileshkin L; Leary A; Bessette P; Putter H; de Boer SM; Horeweg N; Nielsen M; Wezel TV; Bosse T; Creutzberg CL
J Natl Cancer Inst; 2021 Sep; 113(9):1212-1220. PubMed ID: 33693762
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
Germano G; Lamba S; Rospo G; Barault L; Magrì A; Maione F; Russo M; Crisafulli G; Bartolini A; Lerda G; Siravegna G; Mussolin B; Frapolli R; Montone M; Morano F; de Braud F; Amirouchene-Angelozzi N; Marsoni S; D'Incalci M; Orlandi A; Giraudo E; Sartore-Bianchi A; Siena S; Pietrantonio F; Di Nicolantonio F; Bardelli A
Nature; 2017 Dec; 552(7683):116-120. PubMed ID: 29186113
[TBL] [Abstract][Full Text] [Related]
9. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity.
Westcott PMK; Muyas F; Hauck H; Smith OC; Sacks NJ; Ely ZA; Jaeger AM; Rideout WM; Zhang D; Bhutkar A; Beytagh MC; Canner DA; Jaramillo GC; Bronson RT; Naranjo S; Jin A; Patten JJ; Cruz AM; Shanahan SL; Cortes-Ciriano I; Jacks T
Nat Genet; 2023 Oct; 55(10):1686-1695. PubMed ID: 37709863
[TBL] [Abstract][Full Text] [Related]
11. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
12. A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome.
Walker R; Mahmood K; Joo JE; Clendenning M; Georgeson P; Como J; Joseland S; Preston SG; Antill Y; Austin R; Boussioutas A; Bowman M; Burke J; Campbell A; Daneshvar S; Edwards E; Gleeson M; Goodwin A; Harris MT; Henderson A; Higgins M; Hopper JL; Hutchinson RA; Ip E; Isbister J; Kasem K; Marfan H; Milnes D; Ng A; Nichols C; O'Connell S; Pachter N; Pope BJ; Poplawski N; Ragunathan A; Smyth C; Spigelman A; Storey K; Susman R; Taylor JA; Warwick L; Wilding M; Williams R; Win AK; Walsh MD; Macrae FA; Jenkins MA; Rosty C; Winship IM; Buchanan DD;
J Transl Med; 2023 Apr; 21(1):282. PubMed ID: 37101184
[TBL] [Abstract][Full Text] [Related]
13. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
14. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract][Full Text] [Related]
15. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.
Wang J; Yi Y; Xiao Y; Dong L; Liang L; Teng L; Ying JM; Lu T; Liu Y; Guan Y; Pang J; Zhou L; Lu J; Zhang Z; Liu X; Liang X; Zeng X; Yi X; Zhou W; Xia X; Yang L; Zhang J; Kopetz S; Futreal PA; Wu H; Liang Z
Mod Pathol; 2019 Jul; 32(7):1053-1064. PubMed ID: 30723297
[TBL] [Abstract][Full Text] [Related]
18. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
Pasanen A; Loukovaara M; Bützow R
Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
[TBL] [Abstract][Full Text] [Related]
20. Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability.
Cleyle J; Hardy MP; Minati R; Courcelles M; Durette C; Lanoix J; Laverdure JP; Vincent K; Perreault C; Thibault P
Mol Cell Proteomics; 2022 May; 21(5):100228. PubMed ID: 35367648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]